(Sharecast News) - Swiss pharma giant Novartis announced on Wednesday that it is to buy American clinical-stage biopharma firm Regulus for up to $1.7bn, bolstering its position in the renal disease treatment market.
The deal includes an upfront payment of $0.8bn, with a potential additional payment of $0.9bn if regulatory milestones...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE